Humacyte Files for Israeli Marketing Approval of Symvess for Vascular Trauma
HUMA sits 30% above its 52-week low of $0.88.
Summary
Humacyte, a commercial-stage biotechnology company, has submitted a Marketing Authorization Application (MAA) to the Israel Ministry of Health for its Symvess product, an acellular tissue engineered vessel, for arterial trauma repair. This submission marks a significant step in the company's international commercialization strategy for Symvess, which has already received FDA approval for extremity vascular trauma. The company is also pursuing a mechanism to make Symvess available in Israel on a hospital-by-hospital basis prior to full MAA approval, potentially providing an earlier revenue stream. This expansion into the Israeli market, with stated plans for further Middle East expansion, is a positive development for the company's growth prospects and product adoption.
At the time of this announcement, HUMA was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $216.2M. The 52-week trading range was $0.88 to $3.36. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.